and thrombocytosis were defi ned as platelet counts , 100,000/L or . 400,000/L, respectively. Signifi cant leukopenia and leukocytosis were defi ned here as WBC counts of , 4,000 and . 25,000, respectively. The study outcome, 30-day mortality, was defi ned as death by any cause during the period of 30 days after hospital admission.
Statistical Analysis
Categorical variables were described as counts and percentages or examined as predictors using odds ratio and were tested by the x 2 or, if applicable, exact tests. Univariate analysis was used to compare differences in demographic and clinical variables between survivors and nonsurvivors. Comparisons were unpaired, and all tests of signifi cance were two tailed. Continuous variables were compared using Student t test for normally distributed variables and Wilcoxon rank-sum test for non-normally distributed variables.
In order to examine risk factors for mortality at 28 days, a stepwise logistic regression model was used. The outcome variable was mortality at 28 days and the predictor variables included thrombocytosis and other variables listed in Table 1 , which were statistically signifi cant upon univariate analysis ( P , .10) or considered clinically relevant.
To examine the relationship between the continuous values of platelet count and leukocyte count and the likelihood of mortality at 28 days, logistic regression models were used, one for each predictor of interest. Considering that we expected a low number of cases with the outcome variable (mortality), traditional statistical methodology for adjustment of confounding variables would have limited our ability to incorporate multiple variables into the regression model. To overcome this statistical limitation, we decided to use a propensity score that allows for condensing multiple confounding variables into one score to reduce bias and increase precision. In each model, the propensity score created from 33 demographic and clinical variables listed in Table 1 was used to adjust the possibility of confounding effects. [6] [7] [8] All analyses were performed using R software (www.r-project. org), and SPSS software for Windows, version 17.0 (SPSS Inc.; Chicago, IL).
Results
A total of 500 consecutive patients were enrolled in the study. Patient characteristics are reported in Table 1 . Fifty-four subjects (10.8%) died within 30 days of hospital admission. Thrombocytosis was found in 65 (13%) of study patients, 49 (75%) and 16 (25%) in survivors and nonsurvivors, respectively ( P , .0001). Twenty-seven (5.4%) patients had thrombocytopenia, and fi ve of them (18%) died. Signifi cant leukocytosis was seen in 41 (8.2%) patients, 34 (83%) and 7 (17%) in survivors and nonsurvivors, respectively ( P 5 .184). Seven (1.4%) of the patients had leukocytopenia and one of them (14%) died.
The multivariable logistic regression model for mortality up to 30 days in patients with CAP is depicted in Table 2 . Age . 65 years, high PSI risk class, need for mechanical ventilation, and presence of thrombocytosis were all signifi cantly associated with mortality at 30 days. cells exert a rapid, potent, and direct antimicrobial effect that contributes to limiting the infection.
Clinicians have always evaluated the degree of leukocytosis in patients with pneumonia as an indication of systemic infl ammatory response and severity of disease. Thrombocytopenia is also a recognized marker of poor outcomes in patients with pneumonia, due to the association of low platelet counts with disseminated intravascular coagulation and severe sepsis. 4 Abnormalities in the coagulation system can be due to low as well as high platelet count. However, the association between thrombocytosis and clinical outcomes in adult patients with CAP has not been investigated.
Considering that platelets play a crucial role in antimicrobial host defenses and the coagulation system, we hypothesized that an abnormal platelet count may be an important marker to assess severity of disease in patients with CAP. The primary objective of this study was to investigate the association of platelet count at time of hospitalization with mortality at 30 days in patients with CAP. The secondary study objective was to compare platelet count and leukocyte count as predictors of mortality at 30 days in hospitalized patients with CAP.
Materials and Methods

Study Design and Patient Data
This was a retrospective cohort study of consecutive patients admitted with CAP to the Veterans Administration Medical Center of Louisville, Kentucky, between June 2001 and March 2006. Patients enrolled were part of the Community-Acquired Pneumonia Organization international cohort study. 5 Clinical and laboratory data were collected for each patient. These include a total of 33 variables regarding patient's demographic, comorbidity, physical examination, laboratory, and chest radiographic fi ndings. Collected data were used to estimate patient's CAP severity using the pneumonia severity index (PSI) and CRB-65 (confusion, respiratory rate, blood pressure, 65 years of age and older). There were no exclusion criteria. The Veterans Administration Medical Center Institutional Review Board approved the study. Both the study protocol and the data collection form are available on the study website (www.caposite.com).
Study Defi nitions
CAP was defi ned as the presence of a new pulmonary infi ltrate on chest radiograph at the time of hospitalization associated with at least one of the following: (1) new or increased cough, (2) an abnormal temperature ( , 35.6°C or . 37.8°C), (3) an abnormal serum leukocyte count (leukocytosis, left shift, or leukopenia defi ned by local laboratory values). Hypotension was defi ned as a systolic blood pressure , 90 mm Hg or diastolic blood pressure , 60 mm Hg. Alteration of gas exchange was defi ned as Pa o 2 , 60 mm Hg or Pa o 2 /F io 2 , 300 or O 2 saturation , 90%. Thrombocytopenia
The propensity-adjusted model, which accounted for the possible confounding effect of several factors, showed a signifi cant ( P , .0009) association between platelet count and 30-day mortality. Patients with platelet counts in the range of 150,000 cells/ m L to 250,000 cells/ m L had the lowest risk of mortality (approximately 5%) ( Fig 1 ) . Higher platelet counts were associated with a signifi cant increase of the risk of 30-day mortality: patients with thrombocytosis ( . 400,000 cells/ m L) had an estimated risk of mortality in the region of 15%. Likewise, low platelet counts were associated with an increased risk of mortality. CHF 5 congestive heart failure; CRB-65 5 confusion, respiratory rate, blood pressure, 65 years of age and older; CXR 5 chest radiograph; DBP 5 diastolic blood pressure; HCT 5 hematocrit; PSI 5 pneumonia severity index; SBP 5 systolic blood pressure.
The propensity-adjusted model investigating the relationship between the leukocyte count and 30-day mortality did not reveal a signifi cant association, ( P 5 .5114) ( Fig 1 ) .
Discussion
This study indicates that thrombocytopenia and thrombocytosis are signifi cantly associated with mortality in patients with CAP. At time of hospitalization, abnormalities in platelet count are better predictors (95% CI, 1.4-4.6) and a P value of .001 (data not shown).
Important limitations of this study include the fact that the investigation was conducted at a single center and the majority of pneumonia patients enrolled were male, elderly, and had multiple medical comorbidities. This signifi cantly limits the generalizability of our results.
As shown in the multivariable logistic regression model, mortality in hospitalized patients with CAP is associated with severity of disease but it is also independently associated with elevated platelet count. Two possible pathophysiological mechanisms may explain our study fi ndings. Platelets are important infl ammatory cells that can undergo chemotaxis and are able to release numerous proinfl ammatory molecules. 3 In patients with CAP there is an association between levels of infl ammatory cytokines and severity of disease. 11 It can be theorized that thrombocytosis may favor an exaggerated systemic infl ammatory response that, in turn, produces poor outcomes in patients with CAP. Besides this mechanism of plateletinduced systemic infl ammation, another possible mechanism is platelet-induced thrombus formation. Our group recently reported an increased risk of acute myocardial infarction in hospitalized patients of clinical outcomes in patients with CAP when compared with abnormalities in leukocyte count.
Two prior studies, both in pediatric patients, reported an association between thrombocytosis and poor outcomes in patients with CAP. 9, 10 The fi rst study reported that pneumonia in children with thrombocytosis seemed to have a more severe and protracted course, whereas the second study suggested that thrombocytosis was associated with higher likelihood of empyema. The present investigation is the fi rst to report an association of thrombocytosis with mortality in patients with CAP. We also found that thrombocytosis was independently associated with increased length of stay, with an odds ratio of 2.6 Figure 1 . Propensity-adjusted risk of 30-day mortality with 95% CI by platelet count and WBC count at time of hospitalization for patients with community-acquired pneumonia. with CAP that developed clinical failure. 12 Pathologic thrombus formation may contribute to the increased mortality seen in our study. Future research is needed to assess whether elevated platelet count in patients with CAP is just a marker of the infl ammatory response or is in part responsible for the associated increased mortality. In particular, future research should focus on investigating the cause of death for patients with elevated platelet counts, looking specifi cally for acute myocardial infarction, pulmonary embolism, and stroke. The relatively small cohort size of the present study did not allow this analysis. A better understanding of the role of platelets in the outcomes of patients with pneumonia may generate new therapeutic modalities for patients with severe disease.
In summary, during the initial assessment of a patient with pneumonia, physicians might need to consider thrombocytosis as a predictive factor for poor clinical outcomes in addition to the recognized risk associated with thrombocytopenia. Moreover, when evaluating a complete blood count report in patients with CAP, platelet count may be more informative for predicting patient poor outcomes than the more commonly used leukocyte count.
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